Peer-reviewed veterinary case report
Urine markers for detecting meloxicam kidney injury in cats
By Wun, Matthew K et al.·Published in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)·2026·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2), Insulin-Like Growth Factor-Binding Protein-7 (IGFBP-7), and Kidney Injury Molecule-1 (KIM-1) as Biomarkers for the Detection of Meloxicam-Induced Kidney Injury in Cats.
- Species:
- cat
Plain-English summary
A group of healthy female cats was given meloxicam, a common pain medication, for 31 days to see if it could cause kidney injury. Researchers found that two specific urinary markers, IGFBP-7 and KIM-1, were significantly higher in cats that showed signs of kidney damage compared to those that did not receive the medication. This suggests that these markers could help detect early kidney injury in cats treated with meloxicam. However, more research is needed before these tests can be used in everyday veterinary practice.
People also search for: cat kidney injury meloxicam · signs of kidney damage in cats · urinary biomarkers for cat kidney health
Abstract
OBJECTIVE: To evaluate the concentration versus time course profiles of urinary tissue inhibitor of metalloproteinase-2 (TIMP-2), insulin-like growth factor-binding protein-7 (IGFBP-7), and kidney injury molecule-1 (KIM-1) during repeated administrations of meloxicam, and determine whether these profiles differ from saline-treated cats. DESIGN: Placebo-controlled experimental design performed in 2017. ANIMALS: Twelve healthy, adult, purpose-bred female cats. INTERVENTIONS: Cats were randomly allocated to control and treatment groups. Cats in the treatment group (n = 6) received meloxicam 0.3 mg/kg subcutaneously every 24 h for 31 days. Cats in the control group (n = 6) received saline (0.1 mL/kg subcutaneously). MEASUREMENTS AND MAIN RESULTS: Urinary TIMP-2, IGFBP-7, KIM-1, and creatinine were measured every 4-6 days for 31 days, along with serum creatinine. In the treatment group, cats were determined to have renal injury if at least one kidney had histopathological evidence of tubular damage, basement membrane damage, and/or interstitial inflammation. The urinary biomarker concentrations between control and renal injury groups were compared by calculating the area under the curve (AUC) for each biomarker normalized for urine creatinine (UC) concentration versus time course profile and reported as mean ± SE. The AUC values for the two groups were compared statistically using an unpaired, two-tailed t-test. The AUC for urinary IGFBP-7/UC was higher (p = 0.0152) in the treatment group (0.042 ± 0.0062) compared to the control group (0.02676 ± 0.0018). The AUC for urinary KIM-1/UC was higher (p = 0.0083) in the treatment group (0.034 ± 0.0055) compared to the control group (0.019 ± 0.0022). An increase in urinary TIMP-2 was detected in only 50% of the treatment group. CONCLUSIONS: Urinary IGFBP-7 and KIM-1 increase in cats that develop acute kidney injury after repeated meloxicam administration. Further studies are needed before the clinical utility of these molecules as biomarkers for early acute kidney injury detection in cats can be determined.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41549544/